Congenica is a UK company founded on pioneering research from the Wellcome Trust Sanger Institute, NHS clinicians and regional genetic testing laboratories

Congenica translated this research into a gold standard clinical genomic analytics platform, SapientiaTM, which allows genome scale DNA sequence data to be presented within a clinically actionable diagnostic report of genetic disease for patients. This has the potential to revolutionise the diagnosis of rare genetic diseases.

The platform is used by clinicians and researchers for clinical diagnosis, prognosis, and research. Many of the UK Regional Genetics Centres are using SapientiaTM as a decision support platform, as well as clinical laboratories in other countries, including BGI Genomics and UniteGen in China.

SapientiaTM has many other potential applications in personalised medicine, for creating disease registries, to identify patient populations for clinical studies, and for drug target and biomarker identification.

200,000 genetic tests performed each year in the UK for rare diseases.

The platform is used by clinicians and researchers across the world for clinical diagnosis, prognosis, and research. Many of the UK Regional Genetics Centres are using SapientiaTM as a decision support platform, as well as clinical laboratories in other countries.

congenica

SapientiaTM has many other potential applications in personalised medicine, for creating disease registries, to identify patient populations for clinical studies, and for drug target and biomarker identification.

More from our Portfolio

Inivata

HEALTHCARE GROWTH
View company profile www.inivata.com

Morphogen-IX

HEALTHCARE SEED
View company profile www.morphogen-ix.com

Storm Therapeutics

HEALTHCARE SEED
View company profile stormtherapeutics.com/